These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35017312)

  • 1. Efficacy and Safety of Selumetinib in Pediatric Patients With Neurofibromatosis Type 1: A Systematic Review and Meta-analysis.
    Hwang J; Yoon HM; Lee BH; Kim PH; Kim KW
    Neurology; 2022 Mar; 98(9):e938-e946. PubMed ID: 35017312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis.
    Han Y; Li B; Yu X; Liu J; Zhao W; Zhang D; Zhang J
    J Neurol; 2024 May; 271(5):2379-2389. PubMed ID: 38502338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety profile of selumetinib in symptomatic inoperable plexiform neurofibromas.
    Sharawat IK; Panda PK; Sihag RK; Panda P; Dawman L
    J Neurosurg Sci; 2022 Dec; 66(6):501-510. PubMed ID: 35301838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
    Schalkwijk S; Zhou L; Cohen-Rabbie S; Jain L; Freshwater T; So K; He Z; Gioni I; Tomkinson H; Vishwanathan K; Zhou D
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):189-202. PubMed ID: 33903938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.
    Gross AM; Dombi E; Wolters PL; Baldwin A; Dufek A; Herrera K; Martin S; Derdak J; Heisey KS; Whitcomb PM; Steinberg SM; Venzon DJ; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Smith MA; Widemann BC
    Neuro Oncol; 2023 Oct; 25(10):1883-1894. PubMed ID: 37115514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
    Dombi E; Baldwin A; Marcus LJ; Fisher MJ; Weiss B; Kim A; Whitcomb P; Martin S; Aschbacher-Smith LE; Rizvi TA; Wu J; Ershler R; Wolters P; Therrien J; Glod J; Belasco JB; Schorry E; Brofferio A; Starosta AJ; Gillespie A; Doyle AL; Ratner N; Widemann BC
    N Engl J Med; 2016 Dec; 375(26):2550-2560. PubMed ID: 28029918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selumetinib in Children with Inoperable Plexiform Neurofibromas.
    Gross AM; Wolters PL; Dombi E; Baldwin A; Whitcomb P; Fisher MJ; Weiss B; Kim A; Bornhorst M; Shah AC; Martin S; Roderick MC; Pichard DC; Carbonell A; Paul SM; Therrien J; Kapustina O; Heisey K; Clapp DW; Zhang C; Peer CJ; Figg WD; Smith M; Glod J; Blakeley JO; Steinberg SM; Venzon DJ; Doyle LA; Widemann BC
    N Engl J Med; 2020 Apr; 382(15):1430-1442. PubMed ID: 32187457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
    Anderson MK; Johnson M; Thornburg L; Halford Z
    Ann Pharmacother; 2022 Jun; 56(6):716-726. PubMed ID: 34541874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Trametinib in Neurofibromatosis Type 1-Associated Plexiform Neurofibroma and Low-Grade Glioma: A Systematic Review and Meta-Analysis.
    Wang D; Ge L; Guo Z; Li Y; Zhu B; Wang W; Wei C; Li Q; Wang Z
    Pharmaceuticals (Basel); 2022 Jul; 15(8):. PubMed ID: 36015104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selumetinib in the Treatment of Symptomatic Intractable Plexiform Neurofibromas in Neurofibromatosis Type 1: A Prospective Case Series with Emphasis on Side Effects.
    Baldo F; Grasso AG; Cortellazzo Wiel L; Maestro A; Trojniak MP; Murru FM; Basso L; Magnolato A; Bruno I; Barbi E
    Paediatr Drugs; 2020 Aug; 22(4):417-423. PubMed ID: 32533336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: A national real-world case series.
    Coltin H; Perreault S; Larouche V; Black K; Wilson B; Vanan MI; Gupta AA; Morgenstern DA; Parkin PC; Bouffet E; Ramaswamy V
    Pediatr Blood Cancer; 2022 Aug; 69(8):e29633. PubMed ID: 35289492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT.
    Gross AM; Achée C; Hart SE; Brewer L; Baldwin A; Wolters PL; Widemann BC;
    Future Oncol; 2024 May; 20(14):877-890. PubMed ID: 38869947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA Approval Summary: Selumetinib for Plexiform Neurofibroma.
    Casey D; Demko S; Sinha A; Mishra-Kalyani PS; Shen YL; Khasar S; Goheer MA; Helms WS; Pan L; Xu Y; Fan J; Leong R; Liu J; Yang Y; Windsor K; Ou M; Stephens O; Oh B; Reaman GH; Nair A; Shord SS; Bhatnagar V; Daniels SR; Sickafuse S; Goldberg KB; Theoret MR; Pazdur R; Singh H
    Clin Cancer Res; 2021 Aug; 27(15):4142-4146. PubMed ID: 33712511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience.
    Espírito Santo V; Passos J; Nzwalo H; Carvalho I; Santos F; Martins C; Salgado L; Silva CE; Vinhais S; Vilares M; Salgado D; Nunes S
    J Neurooncol; 2020 Apr; 147(2):459-463. PubMed ID: 32108293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
    Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
    BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity.
    Gross AM; Glassberg B; Wolters PL; Dombi E; Baldwin A; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Whitcomb P; Paul SM; Steinberg SM; Venzon DJ; Martin S; Carbonell A; Heisey K; Therrien J; Kapustina O; Dufek A; Derdak J; Smith MA; Widemann BC
    Neuro Oncol; 2022 Nov; 24(11):1978-1988. PubMed ID: 35467749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review.
    Solares I; Viñal D; Morales-Conejo M; Rodriguez-Salas N; Feliu J
    ESMO Open; 2021 Aug; 6(4):100223. PubMed ID: 34388689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Cardiac Function by Echocardiographic Global Longitudinal Strain in a Cohort of Children with Neurofibromatosis Type 1 Treated with Selumetinib.
    Caiffa T; Tessitore A; Magnolato A; Petz M; Bobbo M; Chicco D; D'Agata Mottolese B; Porcari A; Barbi E; Sinagra G; Bruno I
    Paediatr Drugs; 2023 Mar; 25(2):217-224. PubMed ID: 36529809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision oncology in neurofibromatosis type 1: quantification of differential sensitivity to selumetinib in plexiform neurofibromas using single-cell RNA sequencing.
    Bhandarkar AR; Bhandarkar S; Babovic-Vuksanovic D; Raghunathan A; Schwartz J; Spinner RJ
    J Neurooncol; 2024 Aug; 169(1):147-153. PubMed ID: 38739187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.
    Galvin R; Watson AL; Largaespada DA; Ratner N; Osum S; Moertel CL
    Curr Oncol Rep; 2021 Mar; 23(4):45. PubMed ID: 33721151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.